1. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells
   Xiaofang Zhao et al, 2016, Oncotarget CrossRef
2. Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma
   Hector Perez-Montoyo, 2020, Cells CrossRef
3. Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future
   Olga Nigro et al, 2021, Anti-Cancer Drugs CrossRef
4. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
   M Zuo et al, 2015, British Journal of Cancer CrossRef
5. A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report
   Hua-Sheng Shi et al, 2021, Visceral Medicine CrossRef
6. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
   Francesca Corti et al, 2019, Cancer Treatment Reviews CrossRef
7. Unraveling the actin cytoskeleton in the malignant transformation of cholangiocyte biology
   Lea Duwe et al, 2022, Translational Oncology CrossRef
8. Plasma Phosphoproteome and Differential Plasma Phosphoproteins with Opisthorchis Viverrini-Related Cholangiocarcinoma
   Kanawut Kotawong et al, 2015, Asian Pacific Journal of Cancer Prevention CrossRef
9. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells
   Hui Yang et al, 2015, Oncotarget CrossRef
10. Novel Targeted Therapy Strategies for Biliary Tract Cancers and Hepatocellular Carcinoma
    Thomas T DeLeon et al, 2018, Future Oncology CrossRef
11. mTOR Inhibitors in Advanced Biliary Tract Cancers
    Chao-En Wu et al, 2019, International Journal of Molecular Sciences CrossRef
12. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway
    Dong Kee Jang et al, 2020, Biochemical and Biophysical Research Communications CrossRef
13. Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness
    Simone Brivio et al, 2017, World Journal of Hepatology CrossRef
14. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma
    Massimiliano Cadamuro et al, 2018, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
15. Optimum chemotherapy for the management of advanced biliary tract cancer
    Marwan Ghosn, 2015, World Journal of Gastroenterology CrossRef
16. K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines
    Yvonne Yeung et al, 2017, Molecular Oncology CrossRef
17. Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta as a potential biomarker for Opisthorchis viverrini infection and cholangiocarcinoma
    Sattrachai Prasopdee et al, 2022, Parasitology CrossRef
18. Ubiquitin-conjugating enzyme E2T regulates cell proliferation and migration in cholangiocarcinoma
    Fangfeng Liu et al, 2020, Anti-Cancer Drugs CrossRef
19. Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation
    Ji-Lai Bian et al, 2017, World Journal of Gastroenterology CrossRef
20. Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives
    Mirella Pastore et al, 2020, Cells CrossRef
21. Glucose transporter 3 performs a critical role in mTOR-mediated oncogenic glycolysis and tumorigenesis
    YANBIN ZHANG et al, 2015, Oncology Letters CrossRef
22. Differential plasma proteomes of the patients with Opisthorchiasis viverrini and cholangiocarcinoma identify a polymeric immunoglobulin receptor as a potential biomarker
    Sattrachai Prasopdee et al, 2022, Heliyon CrossRef
23. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview
    Simone Brivio et al, 2018, Gene Expression CrossRef